Literature DB >> 15485602

Hypertension and the metabolic syndrome.

John A Farmer1.   

Abstract

The metabolic syndrome is a highly prevalent condition in the United States and it has been estimated from the Third National Health and Nutrition Examination Survey that approximately 40 million individuals fulfill the diagnostic criteria, which include a waist circumference greater than 40 inches in men and 35 inches in women, triglycerides in excess of 150 mg/dL, and a high-density lipoprotein cholesterol under 40 mg/dL in men or under 50 mg/dL in women. Additionally, a blood pressure in excess of 130/85 mm Hg and a fasting plasma glucose above 110 mg/dL is required. The diagnosis of the metabolic syndrome requires at least three of the five major criteria for qualification. Hypertension, dyslipidemia, and diabetes frequently cluster and share common pathogenetic mechanisms, resulting in a complex interplay between these apparently disparate risk factors. This review centers on the common metabolic pathways that are common to the major conditions seen in the metabolic syndrome, and centers on the central role of hypertension and the clinical impact of drug therapy on other metabolic parameters.

Entities:  

Mesh:

Year:  2004        PMID: 15485602     DOI: 10.1007/s11886-004-0050-7

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  19 in total

Review 1.  Angiotensin II and endothelin induce inflammation and thereby promote hypertension-induced end-organ damage.

Authors:  D N Müller; A Fiebeler; J K Park; R Dechend; F C Luft
Journal:  Clin Nephrol       Date:  2003-07       Impact factor: 0.975

2.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

3.  Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men.

Authors:  G Nickenig; A T Bäumer; Y Temur; D Kebben; F Jockenhövel; M Böhm
Journal:  Circulation       Date:  1999-11-23       Impact factor: 29.690

4.  Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey.

Authors:  Earl S Ford; Wayne H Giles; William H Dietz
Journal:  JAMA       Date:  2002-01-16       Impact factor: 56.272

Review 5.  Vascular inflammation: a role in vascular disease in hypertension?

Authors:  Agostino Virdis; Ernesto L Schiffrin
Journal:  Curr Opin Nephrol Hypertens       Date:  2003-03       Impact factor: 2.894

6.  C-reactive protein and glycemic control in adults with diabetes.

Authors:  Dana E King; Arch G Mainous; Thomas A Buchanan; William S Pearson
Journal:  Diabetes Care       Date:  2003-05       Impact factor: 19.112

7.  C-reactive protein and the risk of developing hypertension.

Authors:  Howard D Sesso; Julie E Buring; Nader Rifai; Gavin J Blake; J Michael Gaziano; Paul M Ridker
Journal:  JAMA       Date:  2003-12-10       Impact factor: 56.272

Review 8.  C-reactive protein: risk marker or mediator in atherothrombosis?

Authors:  Ishwarlal Jialal; Sridevi Devaraj; Senthil K Venugopal
Journal:  Hypertension       Date:  2004-05-17       Impact factor: 10.190

9.  Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study).

Authors:  Lars H Lindholm; Mats Persson; Petar Alaupovic; Bo Carlberg; Anders Svensson; Ola Samuelsson
Journal:  J Hypertens       Date:  2003-08       Impact factor: 4.844

10.  Adverse prognostic significance of new diabetes in treated hypertensive subjects.

Authors:  Paolo Verdecchia; Gianpaolo Reboldi; Fabio Angeli; Claudia Borgioni; Roberto Gattobigio; Lucia Filippucci; Silvia Norgiolini; Costanza Bracco; Carlo Porcellati
Journal:  Hypertension       Date:  2004-03-22       Impact factor: 10.190

View more
  3 in total

Review 1.  PPAR ligands: potential therapies for metabolic syndrome.

Authors:  Taro E Akiyama; Peter T Meinke; Joel P Berger
Journal:  Curr Diab Rep       Date:  2005-02       Impact factor: 4.810

2.  Increased energy expenditure, dietary fat wasting, and resistance to diet-induced obesity in mice lacking renin.

Authors:  Nobuyuki Takahashi; Feng Li; Kunjie Hua; Jianbei Deng; Chih-Hong Wang; Robert R Bowers; Timothy J Bartness; Hyung-Suk Kim; Joyce B Harp
Journal:  Cell Metab       Date:  2007-12       Impact factor: 27.287

3.  A Metagenome-Wide Association Study of the Gut Microbiome and Metabolic Syndrome.

Authors:  Qian Qin; Su Yan; Yang Yang; Jingfeng Chen; Tiantian Li; Xinxin Gao; Hang Yan; Youxiang Wang; Jiao Wang; Shoujun Wang; Suying Ding
Journal:  Front Microbiol       Date:  2021-07-16       Impact factor: 5.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.